

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

1 VENABLE LLP  
2 DANIEL S. SILVERMAN (SBN 137864)  
3 Email: dsilverman@venable.com  
4 2049 Century Park East, Suite 2100  
5 Los Angeles, CA 90067  
6 Telephone: (310) 229-9900  
7 Facsimile: (310) 229-9901

8 CANTOR COLBURN LLP  
9 William J. Cass (*Pro Hac Vice*)  
10 Email: wcass@cantorcolburn.com  
11 Keith J. Murphy (*Pro Hac Vice*)  
12 Email: kmurphy@cantorcolburn.com  
13 Andrew J. Ryan (*Pro Hac Vice*)  
14 Email: ryan@cantorcolburn.com  
15 20 Church Street, 22nd Floor  
16 Hartford, CT 06103  
17 Telephone: (860) 286-2929  
18 Facsimile: (860) 286-0115

19 CANTOR COLBURN LLP  
20 Jefferey B. Arnold (*Pro Hac Vice*)  
21 Email: jarnold@cantorcolburn.com  
22 1180 Peachtree Street, Suite 2050  
23 Atlanta, GA 30309  
24 Telephone: (404) 607-9991  
25 Facsimile: (404) 607-9981

26 Attorneys for Defendant and Counterclaimant  
27 PURUS LABS, INC.

28  
UNITED STATES DISTRICT COURT  
CENTRAL DISTRICT OF CALIFORNIA

19 THERMOLIFE INTERNATIONAL,  
20 LLC,

21 Plaintiff,

22 v.

23 BETTER BODY SPORTS, LLC, et al.,

24 Defendants.

CASE NO. CV12-09229 GAF (FFMx)

Hon. Gary A. Feess  
Courtroom 740

**DEFENDANT PURUS LABS, INC.'S  
ANSWER TO PLAINTIFF'S  
COMPLAINT FOR PATENT  
INFRINGEMENT, AFFIRMATIVE  
DEFENSES, COUNTERCLAIMS  
AND DEMAND FOR JURY TRIAL**

Action Filed: October 26, 2012  
Trial Date: None set

2013 JAN -8 PM 4:00  
CLERK U.S. DISTRICT COURT  
CENTRAL DIST. OF CALIF.  
LOS ANGELES  
BY: \_\_\_\_\_

FILED

PURUS LABS, INC.,  
Counterclaimant,  
v.  
THERMOLIFE INTERNATIONAL,  
LLC,  
Counterdefendant.

Now comes the Defendant and Counterclaimant, Purus Labs, Inc. ("Purus Labs") and for its answer, affirmative defenses and counterclaims, alleges as follows:

**I. THE PARTIES**

1. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph one of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

2. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph two of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

3. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph three of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

4. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph four of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

5. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph five of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.



VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

1 15. Admitted.

2 16. Purus Labs is without information sufficient to form a belief as to the  
3 truth of the allegations in paragraph sixteen of the Plaintiff's Complaint and calls  
4 upon Plaintiff to prove the same.

5 17. Purus Labs is without information sufficient to form a belief as to the  
6 truth of the allegations in paragraph seventeen of the Plaintiff's Complaint and  
7 calls upon Plaintiff to prove the same.

8 18. Purus Labs is without information sufficient to form a belief as to the  
9 truth of the allegations in paragraph eighteen of the Plaintiff's Complaint and calls  
10 upon Plaintiff to prove the same.

11 19. Purus Labs is without information sufficient to form a belief as to the  
12 truth of the allegations in paragraph nineteen of the Plaintiff's Complaint and calls  
13 upon Plaintiff to prove the same.

14 20. Purus Labs is without information sufficient to form a belief as to the  
15 truth of the allegations in paragraph twenty of the Plaintiff's Complaint and calls  
16 upon Plaintiff to prove the same.

17 21. Purus Labs is without information sufficient to form a belief as to the  
18 truth of the allegations in paragraph twenty-one of the Plaintiff's Complaint and  
19 calls upon Plaintiff to prove the same.

20 **II. JURISDICTION AND VENUE**

21 22. Admitted in part. Purus Labs admits the complaint alleges an action for  
22 patent infringement under Title 35 of the United States Code. Purus Labs is  
23 without information sufficient to form a belief as to the truth of the allegations in  
24 paragraph twenty-two of the Plaintiff's Complaint and calls upon Plaintiff to prove  
25 the same.

26 23. Denied.  
27  
28

1 24. Purus Labs is without information sufficient to form a belief as to the  
2 truth of the allegations set forth in paragraph twenty-four of the Plaintiff's  
3 Complaint and calls upon Plaintiff to prove the same.

4 25. Purus Labs is without information sufficient to form a belief as to the  
5 truth of the allegations in paragraph twenty-five of the Plaintiff's Complaint and  
6 calls upon Plaintiff to prove the same.

7 **III. THE DEFENDANTS' INFRINGING PRODUCTS**

8 **A. FACTS COMMON TO ALL INFRINGING PRODUCTS AND EACH**  
9 **DEFENDANT**

10 26. Purus Labs is without information sufficient to form a belief as to the  
11 truth of the allegations in paragraph twenty-six of the Plaintiff's Complaint and  
12 calls upon Plaintiff to prove the same.

13 27. Purus Labs is without information sufficient to form a belief as to the  
14 truth of the allegations in paragraph twenty-seven of the Plaintiff's Complaint and  
15 calls upon Plaintiff to prove the same.

16 28. Purus Labs is without information sufficient to form a belief as to the  
17 truth of the allegations in paragraph twenty-eight of the Plaintiff's Complaint and  
18 calls upon Plaintiff to prove the same.

19 29. Purus Labs is without information sufficient to form a belief as to the  
20 truth of the allegations in paragraph twenty-nine of the Plaintiff's Complaint and  
21 calls upon Plaintiff to prove the same.

22 30. Purus Labs is without information sufficient to form a belief as to the  
23 truth of the allegations in paragraph thirty of the Plaintiff's Complaint and calls  
24 upon Plaintiff to prove the same.

25 31. Purus Labs is without information sufficient to form a belief as to the  
26 truth of the allegations in paragraph thirty-one of the Plaintiff's Complaint and  
27 calls upon Plaintiff to prove the same.

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

32. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph thirty-two of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

33. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph thirty-three of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

34. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph thirty-four of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

35. Denied.

36. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph thirty-six of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

37. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph thirty-seven of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

38. Denied.

## **B. PRODUCT-SPECIFIC DETAILS**

### **"D-Aspartic Acid" (Defendant Better Body Sports' Infringing Product)**

39. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph thirty-nine of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

40. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph forty of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

### **"Hyper FX" (One of Defendant BSN's Infringing Products)**



VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

41. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph forty-one of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

42. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph forty-two of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

43. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph forty-three of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

44. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph forty-four of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

**"Evotest" (Defendant BSN's Second Infringing Product)**

45. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph forty-five of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

46. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph forty-six of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

47. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph forty-seven of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

48. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph forty-eight of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

**"D-Aspartic Acid" (Defendant Allmax's Infringing Product)**

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

1           49. Purus Labs is without information sufficient to form a belief as to the  
2 truth of the allegations in paragraph forty-nine of the Plaintiff's Complaint and  
3 calls upon Plaintiff to prove the same.

4           50. Purus Labs is without information sufficient to form a belief as to the  
5 truth of the allegations in paragraph fifty of the Plaintiff's Complaint and calls  
6 upon Plaintiff to prove the same.

7           51. Purus Labs is without information sufficient to form a belief as to the  
8 truth of the allegations in paragraph fifty-one of the Plaintiff's Complaint and calls  
9 upon Plaintiff to prove the same.

10 **"DAA Pure" (Defendant Performance Edge's Infringing Product)**

11           52. Purus Labs is without information sufficient to form a belief as to the  
12 truth of the allegations in paragraph fifty-two of the Plaintiff's Complaint and calls  
13 upon Plaintiff to prove the same.

14           53. Purus Labs is without information sufficient to form a belief as to the  
15 truth of the allegations in paragraph fifty-three of the Plaintiff's Complaint and  
16 calls upon Plaintiff to prove the same.

17 **"Propadrol" (Defendant EST Nutrition's Infringing Product)**

18           54. Purus Labs is without information sufficient to form a belief as to the  
19 truth of the allegations in paragraph fifty-four of the Plaintiff's Complaint and calls  
20 upon Plaintiff to prove the same.

21           55. Purus Labs is without information sufficient to form a belief as to the  
22 truth of the allegations in paragraph fifty-five of the Plaintiff's Complaint and calls  
23 upon Plaintiff to prove the same.

24           56. Purus Labs is without information sufficient to form a belief as to the  
25 truth of the allegations in paragraph fifty-six of the Plaintiff's Complaint and calls  
26 upon Plaintiff to prove the same.

27 **"Bullasterone" (Defendant Hi-Tech's Infringing Product)**



VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

57. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph fifty-seven of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

58. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph fifty-eight of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

59. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph fifty-nine of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

60. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph sixty of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

61. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph sixty-one of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

**"Dagger" (Defendant Infinite Labs' Infringing Product)**

62. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph sixty-two of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

63. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph sixty-three of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

64. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph sixty-four of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

**"Intratest Xtreme (Defendant Lecheek's First Infringing Product)"**

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

65. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph sixty-five of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

66. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph sixty-six of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

67. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph sixty-seven of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

**"Speed X3" (Defendant Lecheek's Second Infringing Product)**

68. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph sixty-eight of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

69. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph sixty-nine of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

70. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph seventy of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

**Testodol X9 (Defendant Lecheek's Third Infringing Product)**

71. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph seventy-one of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

72. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph seventy-two of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

1           73. Purus Labs is without information sufficient to form a belief as to the  
2 truth of the allegations in paragraph seventy-three of the Plaintiff's Complaint and  
3 calls upon Plaintiff to prove the same.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

**"X-Fit Power" (Defendant MHP's Infringing Product)**

74. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph seventy-four of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

75. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph seventy-five of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

76. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph seventy-six of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

77. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph seventy-seven of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

**"NMDA" (Defendant Muscle Warfare's First Infringing Product)**

78. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph seventy-eight of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

79. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph seventy-nine of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

**"MOAB" (Defendant Muscle Warfare's Second Infringing Product)**

80. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph eighty of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

81. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph eighty-one of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

**“Nuke” (Defendant Muscle Warfare’s Third Infringing Product)**

82. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph eighty-two of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

83. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph eighty-three of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

**“Napalm” (Defendant Muscle Warfare’s Fourth Infringing Product)**

84. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph eighty-four of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

85. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph eighty-five of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

**“T-Up” (Defendant Nutrex’s Infringing Product)**

86. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph eighty-six of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

87. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph eighty-seven of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

88. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph eighty-eight of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

89. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph eighty-nine of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

**“Anabolic Freak” (Defendant Pharm Freak Infringing Product)**

90. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph ninety of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

91. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph ninety-one of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

**“D-pol” (Defendant Purus’ Infringing Product)**

92. Admitted.

93. Denied.

94. Denied.

95. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph ninety-five of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

**“Warrior” (Defendant Reaction’s Infringing Product)**

96. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph ninety-six of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

97. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph ninety-seven of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

98. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph ninety-eight of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.



VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

**“Vitality DM” (Defendant Reaction’s Other Infringing Product)**

99. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph ninety-nine of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

100. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph one hundred of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

101. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph one hundred and one of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

**“Pure Test” (Defendant Finaflex’s Infringing Product)**

102. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph one hundred and two of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

103. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph one hundred and three of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

104. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph one hundred and four of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

105. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph one hundred and five of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

**“Revolution PCT” (Defendant Finaflex’s Second Infringing Product)**

106. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph one hundred and six of the Plaintiff’s Complaint and calls upon Plaintiff to prove the same.

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

1 107. Purus Labs is without information sufficient to form a belief as to the  
2 truth of the allegations in paragraph one hundred and seven of the Plaintiff's  
3 Complaint and calls upon Plaintiff to prove the same.

4 108. Purus Labs is without information sufficient to form a belief as to the  
5 truth of the allegations in paragraph one hundred and eight of the Plaintiff's  
6 Complaint and calls upon Plaintiff to prove the same.

7 109. Purus Labs is without information sufficient to form a belief as to the  
8 truth of the allegations in paragraph one hundred and nine of the Plaintiff's  
9 Complaint and calls upon Plaintiff to prove the same.

10 **"Ignite 2" (Defendant Finaflex's Third Infringing Product)**

11 110. Purus Labs is without information sufficient to form a belief as to the  
12 truth of the allegations in paragraph one hundred and ten of the Plaintiff's  
13 Complaint and calls upon Plaintiff to prove the same.

14 111. Purus Labs is without information sufficient to form a belief as to the  
15 truth of the allegations in paragraph one hundred and eleven of the Plaintiff's  
16 Complaint and calls upon Plaintiff to prove the same.

17 112. Purus Labs is without information sufficient to form a belief as to the  
18 truth of the allegations in paragraph one hundred and twelve of the Plaintiff's  
19 Complaint and calls upon Plaintiff to prove the same.

20 113. Purus Labs is without information sufficient to form a belief as to the  
21 truth of the allegations in paragraph one hundred and thirteen of the Plaintiff's  
22 Complaint and calls upon Plaintiff to prove the same.

23 **"V30+" (Defendant SNI's Infringing Product)**

24 114. Purus Labs is without information sufficient to form a belief as to the  
25 truth of the allegations in paragraph one hundred and fourteen of the Plaintiff's  
26 Complaint and calls upon Plaintiff to prove the same.

1 115. Purus Labs is without information sufficient to form a belief as to the  
 2 truth of the allegations in paragraph one hundred and fifteen of the Plaintiff's  
 3 Complaint and calls upon Plaintiff to prove the same.

4 **"D-Aspartic Acid" (Defendant Ethitech's Infringing Product)**

5 116. Purus Labs is without information sufficient to form a belief as to the  
 6 truth of the allegations in paragraph one hundred and sixteen of the Plaintiff's  
 7 Complaint and calls upon Plaintiff to prove the same.

8 117. Purus Labs is without information sufficient to form a belief as to the  
 9 truth of the allegations in paragraph one hundred and seventeen of the Plaintiff's  
 10 Complaint and calls upon Plaintiff to prove the same.

11 **IV. THE DEFENDANTS' INFRINGEMENTS**

12 118. Denied.

13 **A. DIRECT INFRINGEMENTS**

14 119. Denied.

15 120. Denied.

16 121. Denied.

17 **B. INDIRECT INFRINGEMENTS**

18 122. Denied.

19 123. Denied.

20 124. Denied.

21 125. Denied.

22 126. Denied.

23 127. Denied.

24 128. Denied.

25 129. Denied.

26 130. Denied.

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

131. Purus Labs admits that Plaintiff sent communications to Purus Labs between June 2012 and October 2012 to notify them of the patent and their alleged infringements. Purus Labs is without information sufficient to form a belief as to the truth of the remaining allegations contained in paragraph one hundred thirty-one of the Plaintiff's Complaint, and calls upon Plaintiff to prove the same.

132. Purus Labs is without information sufficient to form a belief as to the truth of the allegations in paragraph one hundred and thirty-two of the Plaintiff's Complaint and calls upon Plaintiff to prove the same.

133. Denied.

134. Denied.

135. Denied.

136. Denied.

137. Denied.

138. Denied.

139. Denied.

## V. FIRST CAUSE OF ACTION

### Infringement of U.S. Patent NO, 8,202,908

140. Purus Labs repeats and re-alleges its responses to the allegations of the foregoing paragraphs of this Complaint as if fully set forth herein.

141. Denied.

142. Denied.

143. Denied.

144. Denied.

145. Denied.

146. Denied.

147. Denied.

148. Denied.

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

1 149. Denied.

2 150. Denied.

3 151. Denied.

4 152. Denied.

5 153. Denied.

6 154. Denied.

7 155. Denied.

8 156. Denied.

9 157. Denied.

10 158. Denied.

11 159. Denied.

12 **AFFIRMATIVE DEFENSES**

13 **FIRST AFFIRMATIVE DEFENSE**

14 Plaintiff's Complaint fails to state a claim upon which relief may be granted.

15 **SECOND AFFIRMATIVE DEFENSE**

16 Purus Labs has not engaged in any acts that would constitute infringement of  
17 any valid and enforceable patent in suit.

18 **THIRD AFFIRMATIVE DEFENSE**

19 The patent-in-suit is invalid for failure to comply with the statutory  
20 provisions for patentability and validity set forth Title 35 of the United States  
21 Code, including one or more of 35 U.S.C. §§ 101, 102, 103, 112, 115, 116 and  
22 256, for the following reasons:

23 a. The alleged invention was known or used by others in this country, or  
24 patented or described in a printed publication in this or a foreign country, more  
25 than one year prior to the date of the application for a patent in the United States.

26 b. The alleged invention was known or used by others in this country, or  
27 patented or described in a printed publication in this or a foreign country or in  
28

1 public use or on sale in this country, more than one year prior to the date of the  
2 application for patent in the United States.

3 c. The alleged invention was described in a patent granted on an  
4 application for a patent by another filed in the United States before the invention  
5 thereof by the alleged patentees, or on an international application by another  
6 which complied with the requisite statutes.

7 d. The patentees did not themselves invent the subject matter sought to  
8 be patented.

9 e. Before the alleged invention by the patentees the alleged invention  
10 was made in this country by another who had not abandoned, suppressed or  
11 concealed it.

12 f. The alleged invention was obvious at the time of the invention to a  
13 person having ordinary skill in the art.

14 g. The specifications of the patent does not comply with the  
15 requirements set forth in 35 U.S.C. §112, including but not limited to the best  
16 mode requirement and enablement requirement.

17 h. The patent does not particularly point out and distinctly claim the  
18 invention.

19 i. One or more of the correct inventors were not named on the asserted  
20 patent.

21 j. The inventor committed inequitable conduct before the United States  
22 Patent and Trademark Office during the prosecution of the '908 patent, as specified  
23 in greater detail below.

24 **FOURTH AFFIRMATIVE DEFENSE**

25 Plaintiff is estopped from asserting a scope for the claims of the asserted  
26 patent-in-suit that would cover any product made, used, sold and/or offered for sale  
27  
28



1 by Purus Labs by representations, arguments, and/or amendments made during  
2 prosecution of the asserted patent before the PTO.

### 3 **FIFTH AFFIRMATIVE DEFENSE**

4 Plaintiff is not entitled to any relief or recovery by reason of its coming into  
5 this Court with unclean hands in seeking to enforce patent that Plaintiff knew on  
6 information and belief to be invalid, unenforceable, and/or not infringed.

### 7 **SIXTH AFFIRMATIVE DEFENSE**

8 Plaintiff is not entitled to any equitable relief or recovery because it has a  
9 full, complete and adequate remedy at law.

### 10 **SEVENTH AFFIRMATIVE DEFENSE**

11 Plaintiff is not entitled to any equitable relief or recovery because it has  
12 unclean hands.

### 13 **COUNTERCLAIMS**

14 Pursuant to Federal Rule of Civil Procedure 13, Purus Labs' Counterclaims  
15 against Plaintiff are as follows:

### 16 **THE PARTIES**

17 1. The co-Defendant/Plaintiff-in-Counterclaim, Purus Labs, Inc., is a  
18 company organized under the laws of Texas, with its principal place of business at  
19 11370 Pagemill Road, in Dallas, Texas, 75243.

20 2. The Plaintiff/Defendant-in-Counterclaim allegedly is a limited  
21 liability company organized and existing under the laws of Arizona, with a place of  
22 business at 1811 Ocean Front Walk in Venice, California, 90291.

23 3. Defendant Better Body Sports, LLC is a named Defendant in this  
24 litigation.

25 4. Defendant Bio-Engineered Supplements and Nutrition, Inc. is a  
26 named Defendant in this litigation.

19. Defendant Tiger Fitness, Inc. d/b/a Ethitech is a named Defendant in this litigation.

20. Defendant All Star Health is a named Defendant in this litigation.

### **JURISDICTION AND VENUE**

21. This counterclaim is brought pursuant to the Federal Declaratory Judgment Act, 28 U.S.C. §2201, et seq. The Complaint in this action alleges that Purus Labs has infringed the patent-in-suit and gives rise to an actual case or controversy under 28 U.S.C. §§ 2201 and 2202.

22. This counterclaim arises under the patent laws of the United States, 35 U.S.C. § 1, et seq.

23. This Court has subject matter jurisdiction over this counterclaim pursuant to 28 U.S.C. §§ 1338, 2201, and 2202.

24. This Court has subject matter jurisdiction over this counterclaim pursuant to 28 U.S.C. §§ 1338, 2201, and 2202.

25. Venue for this Counterclaim in this District is proper under 28 U.S.C. §§ 1391 as this Counterclaim arises from the Complaint. Purus Labs reserves the right to contest venue of the underlying action.

26. Purus Labs is entitled to declaratory relief because, although Purus Labs has not infringed and is not infringing the patent-in-suit, Purus Labs will use accused apparatus and methods as claimed in the patent-in-suit after the patent-in-suit are declared not infringed, invalid, and/or unenforceable

### **FACTUAL BACKGROUND**

27. On or about June 29, 2012, the United States Patent and Trademark Office issued U.S. Patent No. 8,202,908 ("the '908 patent") entitled "D-Aspartic Acid Supplement," indicating the inventor as Patrick Arnold and being assigned to Thermolife International, LLC. The Plaintiff asserts the named Defendants allegedly committed the tort of patent infringement within the State of California, and allegedly infringed the '908 patent by either shipping, selling, distributing, offering for sale, advertising, or continued to ship, distribute, offer for sale and

1 advertise the accused products listed in Plaintiff's Complaint in this judicial  
2 district.

### 3 COUNT I

#### 4 **(DECLARATORY JUDGMENT OF NON-INFRINGEMENT)**

5 28. Purus Labs repeats and realleges Paragraphs 1 through 27 above, as  
6 though fully set forth herein.

7 29. Purus Labs has not directly infringed and do not directly infringe any  
8 or all of the claims of the patent in suit under 35 U.S.C. § 271 (a).

9 30. Purus Labs has not actively induced and does not actively induce  
10 infringement of any or all of claims of the patent in suit under 35 U.S.C. § 271 (b).

11 31. Purus Labs has not contributed to and does not contribute to  
12 infringement of any or all of the claims of the patent in suit under 35 U.S.C. § 271  
13 (c).

14 32. Purus Labs is therefore entitled to a declaratory judgment that Purus  
15 Labs does not directly or indirectly infringe any or all of the claims of the patent-  
16 in-suit and to such further injunctive relief as may be just and proper.

### 17 COUNT II

#### 18 **(DECLARATORY JUDGMENT OF PATENT INVALIDITY)**

19 33. Purus Labs incorporates the allegations set forth in paragraphs 1  
20 through 32 above by reference as if fully set forth herein.

21 34. The patent-in-suit are invalid for failure to comply with the statutory  
22 provisions for patentability and validity set forth Title 35 of the United States  
23 Code, including one or more of 35 U.S.C. §§ 101, 102, 103, 112, 115, 116 and  
24 256, for the following reasons:

25 a. The alleged invention was known or used by others in this country, or  
26 patented or described in a printed publication in this or a foreign country, more  
27 than one year prior to the date of the application for a patent in the United States.

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

1           b. The alleged invention was known or used by others in this country, or  
2 patented or described in a printed publication in this or a foreign country or in  
3 public use or on sale in this country, more than one year prior to the date of the  
4 application for patent in the United States.

5           c. The alleged invention was described in a patent granted on an  
6 application for a patent by another filed in the United States before the invention  
7 thereof by the alleged patentees, or on an international application by another  
8 which complied with the requisite statutes.

9           d. The patentees did not themselves invent the subject matter sought to  
10 be patented.

11           e. Before the alleged invention by the patentees the alleged invention  
12 was made in this country by another who had not abandoned, suppressed or  
13 concealed it.

14           f. The alleged invention was obvious at the time of the invention to a  
15 person having ordinary skill in the art.

16           g. The specifications of the patent does not comply with the  
17 requirements set forth in 35 U.S.C. §112, including but not limited to the best  
18 mode requirement and enablement requirement.

19           h. The patent does not particularly point out and distinctly claim the  
20 invention.

21           i. One or more of the correct inventors were not named on the asserted  
22 patent.

23           35. Purus Labs is therefore entitled to a declaratory judgment that some or  
24 all of the claims of the patent-in-suit are invalid and to such further relief as may  
25 be just and proper.  
26  
27  
28

**COUNT III****(INEQUITABLE CONDUCT)**

36. Purus Labs incorporates the allegations set forth in paragraphs 1 through 35 above by reference as if fully set forth herein.

37. D-aspartic acid is an enantiomer of aspartic acid and is known as dextrorotary aspartic acid or by the abbreviations (+)-aspartic acid, (d)-aspartic acid, or D-aspartic acid.

38. On or about March 28, 2008, Patrick Arnold submitted a provisional patent application to the United States Patent and Trademark Office (hereinafter the "Patent Office") for a D-Aspartic acid supplement. The application was assigned application no. 61/072,254.

40. On or about March 27, 2009, Patrick Arnold filed a formal patent application, application no. 12/383,682, which claimed priority to provisional patent application no. 61/072,254.

41. The asserted '908 patent issued from the formal patent application filed on March 27, 2009, application no. 12/383,682.

42. The asserted '908 patent lists Patrick Arnold as the sole inventor.

43. On or about March 29, 2009, the inventor, Patrick Arnold, executed a *Declaration and Power of Attorney*, in which he acknowledged, *inter alia*, "the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56." The declaration was filed with the Patent Office.

44. In his patent application, no. 12/383682, Mr. Arnold represented to the Patent Office, *inter alia*, that:

No studies have examined the effects of D-aspartic acid or N-methyl-D-aspartate on male humans. It is well known that different species of mammals often have different responses to hormones. Therefore, it is unknown whether, and to what degree, the administration of D-aspartic acid compounds in different ways and at different levels to male humans causes



1 an increase in levels of testosterone, growth hormone, and insulin-like  
2 growth factor 1.

3 Accordingly, there is a demand for a method of improving the physical  
4 condition of adult male humans of all ages by increasing their levels of  
5 testosterone, growth hormone, and insulin-like growth factor 1 without the  
6 administration of hormones or prohormones.

7 45. In his patent application, no. 12/383682, Mr. Arnold represented to  
8 the Patent Office, *inter alia*, that:

9 One general object of this invention is to provide an improved method  
10 of enhancing the physical condition of adult male humans of all ages by  
11 increasing their levels of testosterone, growth hormone, and/or insulin-like  
12 growth factor 1 without the administration of hormones.

13 I have invented a method of improving the physical condition of an  
14 adult male human. The method comprises administering an effective amount  
15 of a D-aspartic acid compound to an adult male human.

16 The method of this invention improves the physical condition of adult  
17 male humans of all ages by increasing their levels of testosterone, growth  
18 hormone, and/or insulin-like growth factor 1 without the administration of  
19 hormones. The method comprises the administration of D-aspartic acid  
20 and/or its biological equivalent derivate compounds. D-aspartic acid is a  
21 chemical that is present in the human body and is generally recognized as  
22 safe.

23 46. In his patent application, no. 12/383682, Mr. Arnold represented to  
24 the Patent Office, *inter alia*, that:

25 1. The Invention In General

26 The method of the invention comprises the administration of an effective  
27 amount of a D-aspartic acid compound to adult human males. It has been  
28 surprisingly found that the administration causes an increase in the levels of  
testosterone, growth hormone, and insulin-like growth factor 1. Increases in  
these hormones cause, in turn, an improvement in the physical condition of  
the males.

2. The D-Aspartic Acid Compound

1 Suitable D-aspartic acid compounds include D-aspartic acid, D-aspartate  
2 salts, D-aspartate esters, and other functionally equivalent derivatives such  
3 as N-methyl-D-aspartic acid. The D-aspartic acid compound is suitable in its  
4 enantiomeric form or as the racemic mixture. The preferred compound is  
5 DL-aspartic acid because of its ready availability and low cost.

### 6 3. Administration

7 The D-aspartic acid compound is administered in any known way that  
8 results in the compound entering the bloodstream. For example, the  
9 compound is orally ingested, injected directly into the bloodstream,  
10 administered via patches, and the like. The preferred method of  
11 administration is by oral ingestion. D-aspartic acid is well tolerated and is  
12 effectively taken into the bloodstream through the digestive tract.

13 The D-aspartic acid compound is conveniently ingested as a powder or is  
14 dissolved in a suitable liquid. For example, D-aspartic acid has substantial  
15 solubility in water and is well suited for addition to conventional aqueous  
16 beverages. The D-aspartic acid may have synergistic results with other  
17 common nutritional supplements, such as androst-4-ene-3,6,17-trione,  
18 marketed as 6-OXO supplement by Proviant Technologies, Inc. of  
19 Champaign, Ill.

### 20 4. Effective Amount

21 The D-aspartic acid compound is administered in an amount that is effective  
22 to increase the levels of testosterone, growth hormone, and/or insulin-like  
23 growth factor 1 in the recipient. In general, the D-aspartic acid compound is  
24 administered in an amount of about 1 to 100 grams per day, preferably about  
25 1 to 20 grams per day, and most preferably about 5 to 10 grams per day,  
26 computed on the basis of equivalent molar amount of D-aspartic acid. In  
27 other words, if the DL-aspartic acid racemic modification is used, the  
28 amounts are doubled. If a derivative is used having a molecular weight ten  
percent greater than that of D-aspartic acid, the amounts are increased by ten  
percent to provide the same equivalent molar amount.

### 5. Benefits

The administration of an effective amount of a D-aspartic acid compound  
has many beneficial effects on adult male humans. The administration  
causes an increase in the levels of testosterone, growth hormone, and/or  
insulin-like growth factor 1 in the recipient, regardless of age. The increases  
in these hormones, in turn, are believed to cause a large number of  
improvements in physical condition, including an increase in muscle mass,

1 an increase in strength, a decrease in fat, and a reduction in various aging  
2 characteristics. Increases in these hormones are also believed to cause an  
3 improvement in sexual performance.

4 47. The pending patent claims in the application, no. 12/383,682, were  
5 originally stated as follows:

6 1. A method of improving the physical condition of an adult male  
7 human, the method comprising administering an effective amount of a D-  
8 aspartic acid compound to an adult male human.

9 2. The method of claim 1 wherein the D-aspartic acid compound is  
10 administered by oral ingestion.

11 3. The method of claim 2 wherein the D-aspartic acid compound is  
12 administered in an amount of about 1 to 20 grams of D-aspartic acid  
13 equivalent.

14 4. The method of claim 3 wherein the D-aspartic acid compound is  
15 administered as a racemic mixture.

16 5. The method of claim 1 wherein the D-aspartic acid compound  
17 comprises D-aspartic acid.

18 6. The method of claim 1 wherein the D-aspartic acid compound  
19 comprises N-methyl-D-aspartic acid.

20 7. The method of claim 1 wherein the D-aspartic acid compound  
21 comprises a salt or an ester of D-aspartic acid.

22 8. A method of improving the physical condition of an adult male human  
23 increasing his levels of testosterone, growth hormone, and/or insulin-like  
24 growth factor 1, the method comprising administering an effective amount  
25 of a D-aspartic acid compound to an adult male human.

26 48. On or about June 7, 2011, the Patent Office issued an Office Action  
27 Summary, and rejected the pending claims. The examiner noted claims 1 – 8 were  
28 rejected under 35 U.S.C. § 103(a) as being unpatentable over Estienne *et al.*, U.S.  
Patent No. 5,691,377. The examiner rejected claims 1 – 8 under 35 U.S.C. §  
103(a) as being unpatentable over Simone, U.S. Patent No. 5,397,786, in view of  
Pantaleone *et al.*, U.S. Patent No. 5,834,259, and further view of Estienne *et al.*,  
U.S. Patent No. 5,691,377. The examiner rejected Claims 1-5, 7 and 8 under 35  
U.S. C. 103(a) as being unpatentable over Estienne *et al.* (U.S. 5,691,377) in view

1 of Pantaleone *et al.* (U.S. 5,834,259). The examiner also rejected claim 1 – 8  
2 under 35 U.S. C. 103(a) as being unpatentable over D’Aniello (Applicant cited  
3 IDS: Brain Research Reviews, 2007, 53, 215 – 234).

4 49. On or about December 7, 2011, the inventor, through his counsel,  
5 filed a Response to Office Action Dated June 7, 2011. In the response, the  
6 inventor, through his counsel, represented that there was no teaching or suggestion  
7 from the prior art cited to increase testosterone levels in human males with the  
8 administration of D-aspartic acid. In particular, the inventor, stated, inter alia:

9  
10 D’Aniello describes the effect of intravenous administration of D-  
11 aspartic acid in rats. This results in increase in LH and testosterone in rats.  
12 However, the Examiner makes two false assumptions here: 1) That intra-  
13 peritoneal administration should have the same effect as oral administration;  
14 and 2) That if something is effective on rats it should have the same effect  
15 on humans.

16 For the first false assumption, a lot of drugs have no effect when  
17 administered orally due to low absorption/bioavailability, extensive  
18 metabolism, destruction in stomach acidic, p.h., inability to reach target  
19 tissues, inability to reach high enough blood concentrations, etc. Therefore,  
20 they exist only in injectionable forms. Examples include Heparin,  
21 Adrenaline (an aminoacid metabolite), benzylpenicilline, etc. Thousands of  
22 examples can be found. The use of a compound parenterally does in no way  
23 make obvious its use for the same purpose orally nor does it make obvious  
24 the dosing scheme and regime to achieve results.

25 For the second false assumption, if we were to assume that rat studies  
26 had the same effect on humans, no human clinical trials would exist. Many,  
27 many drugs and supplements despite showing promising results in rats show  
28 disappointment or even opposite results in humans. . .

Thus, in no way does the effect of the compound on rats render  
obvious it’s therapeutic use in humans . . .

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

1           50. On or about December 7, 2011, the inventor, through his counsel,  
2 filed a Response to Office Action Dated June 7, 2011. In the response, the  
3 inventor, through his counsel, represented:

4           The applicant, prior to applying for the patent, conducted research to prove  
5 D-aspartic acid does indeed increase testosterone levels in humans and  
6 established a dosing regime. This by itself is true research and the patent  
7 office should endorse it as it promotes invention. . .

8           The applicants findings are further confirmed by the following study, which  
9 further proved the applicant did indeed spend time and money to research  
10 the compound before applying [citing *The Role and Molecular mechanism*  
11 *of D-aspartic Acid in the Release and Synthesis of L.H. and Testosterone in*  
12 *Humans and Rats*, Enza Topo et al, Reproductive Biology Endocrinology,  
2009; 7:120.]

13           51. On or about December 22, 2011, the inventor, through his counsel,  
14 filed a Supplemental Response to Office Action Dated June 7, 2011. In the  
15 response, the inventor, through his counsel, represented:

16           In addition to what was already submitted in the Response filed  
17 December 7, 2011 (hereby incorporated by reference), Applicant notes the  
18 following.

19           D'Aniello describes the effect of intravenous administration of D-  
20 aspartic acid in rats. This results in increase in L.H and testosterone in rats.  
21 However, the Examiner makes two false assumptions here: 1) That intra-  
22 peritoneal administration should have the same effect as oral administration;  
23 and 2) That if something is effective on rats it should have the same effect  
24 on humans. . .

25           In addition as we previously stated, the researchers of the foregoing  
26 study themselves exclaimed at the beginning of the study in the background  
27 section that (emphasis added) [citing *The Role and Molecular mechanism of*  
28 *D-aspartic Acid in the Release and Synthesis of L.H. and Testosterone in*  
*Humans and Rats*, Enza Topo et al, Reproductive Biology Endocrinology,  
2009; 7:120]:



“Although numerous studies have been conducted on this matter, no investigations have been until now on the effects of D-Asp on the secretion of LH and testosterone in humans, and neither has the molecular mechanism by which D-Asp triggers its action in the synthesis and release of hormones investigated”

By their very own words the effects of DAA at the time of the study (almost two years after the priority date of the present patent application) on LH and testosterone secretion in HUMANS remained unknown.

52. On or about January 12, 2012, the Patent Office issued a final rejection in an Office Action mailed on January 17, 2012. The examiner noted claims 1 – 5, 7, 8 were rejected under 35 U.S.C. § 103(a) as being unpatentable over Estienne *et al.*, U.S. Patent No. 5,691,377, in view of Pantaleone *et al.*, U.S. Patent No. 5,834,259.

The examiner rejected claims 1 – 5, 7, 8 under 35 U.S.C. § 103(a) as being unpatentable over Simone, U.S. Patent No. 5,397,786, in view of Pantaleone *et al.*, U.S. Patent No. 5,834,259. The examiner also rejected claim 1 – 5, 7, 8 under 35 U.S.C. 103(a) as being unpatentable over D’Aniello (Applicant cited IDS: Brain Research Reviews, 2007, 53, 215 – 234).

53. On or about April 17, 2012, the inventor, through his counsel, filed an Amendment After Final Rejection, wherein he amended claim 1 and 3, and cancelled claims 2, and 5 – 8. Claim 1 was amended, *inter alia*, to include the Markush group “selected from the group consisting of D-aspartic acid, D-Aspartate salts, and D-aspartate esters” purportedly to distinguish the prior art.

54. On or about April 17, 2012, the inventor, through his counsel, made the following statements, *inter alia*, to the Patent Office:

This study/article is not prior art. Therefore, because it is peer reviewed, scrutinized, etc. this article is strong evidence that the present invention is not obvious, [citing *The Role and Molecular mechanism of D-aspartic Acid*



1 *in the Release and Synthesis of L.H. and Testosterone in Humans and Rats*,  
 2 Enza Topo et al, Reproductive Biology Endocrinology, 2009; 7:120] . . .

3 Thus, by their very own words the effects of DAA at the time of the study  
 4 (almost two years after the priority date of the patent application) on LH and  
 testosterone secretion on HUMANS remained unknown. . .

5 The examiner argues because NMDA is an analog compound of D-aspartic  
 6 Acid a person of ordinary skill in the art would be motivated use [sic] for the  
 7 same purposes. The examiner further argues (without evidence whatsoever  
 8 placed on the record) that they are the “same compound”, and that NMDA  
 9 (even though not taught in Estiene) would increase levels of testosterone,  
 growth hormone, and/or insulin-like growth factor 1 as Applicant claimed  
 for D-Aspartic acid in Claim 8. . .

10 Claim 1 has been amended. Among other things, claim 1 includes the  
 11 Markush group “ a D-aspartic acid, D-Aspartate salts, and D-aspartate  
 12 esters” . . .

13 Moreover the presumption of obvious based on a reference disclosing  
 14 structurally similar compounds may be over come where there is a showing  
 15 there is no reasonable expectation of similar properties in structurally similar  
 16 compounds . . . [emphasis in the original]

17 As evidence that there is no reasonable expectation of similar properties in  
 18 DAA as compared to NMDA . . .

19 55. On or about May 10, 2012, the Patent Office issued Notice of  
 20 Allowance. In the Notice, the examiner stated several “Reasons for Allowance,”  
 21 including, inter alia:

22 Applicant’s arguments have been fully considered and found persuasive . . .

23 The closest prior art are Estienne (U.S. 5,591,377), Simone (US 5,397,786)  
 24 and D’Aniello (Applicant cited IDS: Brain Research Reviews, 2007, 53,  
 25 215-234) . . .

26 The prior art D’Aniello (Brain Research Reviews, 2007) does not describe  
 27 oral administration of D-Asp or do not teach administration of D-Asp to  
 28

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

1 humans. The effect of D-Asp at the time of the instant application was filed  
2 on LH and testosterone secretion on humans remained unknown.

3 56. At all times relevant thereto, the arguments made to the Patent Office  
4 during the prosecution of the '908 patent to overcome the various prior art  
5 rejections were made to convince the Patent Office that the effect of D-aspartic at  
6 the time of the patent application was filed on LH and testosterone secretion on  
7 humans remained unknown.

8 57. At all times relevant hereto, the inventor, Patrick Arnold, frequently  
9 commented on the internet concerning the topics of fitness and supplements,  
10 including methods of increasing testosterone.

11 58. On or about October 10, 1996, in an on-line discussion concerning the  
12 "Best Way to Legally Increase Testosterone?", the inventor Patrick Arnold  
13 disclosed "D-aspartic acid (or N-methyl-D-aspartate." This statement was publicly  
14 posted in a forum specifically addressing "good, safe and legal methods of  
15 increasing testosterone" in human males.

16 59. At all times relevant hereto, the arguments made to the Patent Office  
17 during the prosecution of the '908 patent to convince the Patent Office that the  
18 effect of D-aspartic at the time of the patent application was filed on LH and  
19 testosterone secretion on humans remained unknown were false and deceptive.

20 60. At all times relevant hereto, the statements made to the Patent Office  
21 in the application(s) that matured into '908 patent that the effect of D-aspartic at  
22 the time of the patent application was filed on LH and testosterone secretion on  
23 humans remained unknown were false and deceptive.

24 61. At all times relevant hereto, during the prosecution of the '908 patent,  
25 the inventor, Patrick Arnold, withheld information material to the patentability  
26 concerning the subject matter of the '908 patent, including but not limited to,  
27

whether the effect of D-aspartic at the time of the patent application was filed on LH and testosterone secretion on humans remained unknown.

62. The inventor, Patrick Arnold, publically disclosed in a printed media on October 10, 1996, that D-aspartic acid and N-methyl-D-aspartate increases testosterone, such statement was material to patentability, and Mr. Arnold failed to report this public disclosure to the Patent Office, which was his duty under 37 C.F.R. § 1.56.

63. At all times relevant hereto, the above recited acts constituted fraud and/or inequitable conduct in the proceedings before the Patent Office during the prosecution of the '908 patent.

64. Purus Labs is therefore entitled to judgment that the '908 patent is unenforceable, a declaration that this case is exceptional in favor of MHP under 35 U.S.C. § 285 and that Purus Labs be awarded its reasonable attorneys' fees and expenses.

### **PRAYER FOR RELIEF**

WHEREFORE, Purus Labs prays for the following relief:

A. That Judgment be entered in favor of Purus Labs and against Plaintiff on each and every count of the Complaint and on each and every count of its Counterclaim;

B. That Judgment be entered declaring that neither Purus Labs nor the Purus Labs' products have not infringed U.S. Patent 8,202,908;

C. That Judgment be entered declaring that Plaintiff is equitably estopped from alleging infringement of the '908;

D. That Judgment be entered declaring that Plaintiff is precluded from obtaining injunctive relief, money damages, costs, and/or attorneys' fees for any alleged infringement by Purus Labs and/or the Purus Labs' products;

- 1 E. That Judgment be entered declaring the claims of the '908 patent invalid;
- 2 F. That Judgment be entered permanently enjoining and restraining
- 3 Plaintiff, its officers, agents, servants, employees and attorneys, and all others
- 4 acting for, on behalf of, or in active concert or participation with any of them, from
- 5 stating, implying, or suggesting that Purus Labs infringes the patent-in-suit;
- 6 G. That Judgment be entered declaring that this case is exceptional in favor
- 7 of Purus Labs under 35 U.S.C. § 285 and that Purus Labs be awarded its
- 8 reasonable attorneys' fees and expenses;
- 9 H. That Purus Labs be awarded its costs in this action; and
- 10 I. That Purus Labs be awarded such other and further relief as the Court
- 11 may deem just and proper.

12 ///

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

**DEMAND FOR JURY TRIAL**

Purus Labs demands a trial by jury of all issues so triable in this action.

Dated: January 2, 2013



VENABLE LLP

By:   
Daniel S. Silverman

And

Dated: January 2, 2013

CANTOR COLBURN LLP

By:   
William J. Cass 

Attorneys for Defendant and  
Counterclaimant  
PURUS LABS, INC.

VENABLE LLP  
2049 CENTURY PARK EAST, SUITE 2100  
LOS ANGELES, CA 90067  
310-229-9900

**PROOF OF SERVICE**

STATE OF CALIFORNIA )  
COUNTY OF LOS ANGELES ) ss.

I am employed in the County of Los Angeles, State of California. I am over the age of 18 and not a party to the within action; my business address is Venable LLP, 2049 Century Park East, Suite 2100, Los Angeles, California.

On **January 8, 2013**, I served a copy ☒ / original ☐ of the foregoing document(s) described as **DEFENDANT PURUS LABS, INC.'S ANSWER TO PLAINTIFF'S COMPLAINT FOR PATENT INFRINGEMENT, AFFIRMATIVE DEFENSES, COUNTERCLAIMS AND DEMAND FOR JURY TRIAL** on the interested parties in this action addressed as follows

SEE ATTACHED MAILING LIST

☒ By placing true copies thereof enclosed in a sealed envelope(s) addressed as stated above.

☒ **BY MAIL (FRCP 5(b)(1)(C)):** I am readily familiar with the firm's practice of collection and processing correspondence for mailing with the U.S. Postal Service. Under that practice such envelope(s) is deposited with the U.S. postal service on the same day this declaration was executed, with postage thereon fully prepaid at 2049 Century Park East, Suite 2100, Los Angeles, California, in the ordinary course of business.

I declare that I am employed in the office of a member of the Bar of this Court at whose direction the service was made. I declare under penalty of perjury under the laws of the United States of America that the above is true and correct.

Executed on January 8, 2013, at Los Angeles, California.

  
Jan Contreras

**MAILING LIST**

Richard H. Hikida  
 Scott J. Ferrell  
 Tyler J. Woods  
 Newport Trial Group  
 895 Dove Street, Suite 425  
 Newport Beach, CA 92660

*Attorneys for Plaintiff*

Eric Anvari  
 Law Office of Eric Anvari  
 21112 Ventura Blvd.  
 Woodland Hills, CA 91364-2103

*Attorneys for Infinite Labs LLC*

Shyam Dixit  
 Dixit Law Firm PA  
 3030 North Rocky Point Drive West  
 Suite 260  
 Tampa, FL 33607

Derek A. Newman  
 Newman Du Wors LLP  
 100 Wilshire blvd., Suite 950  
 Santa Monica, CA 90401

*Attorneys for Muscle Warfare, Inc.*

William E. Thomson, Jr.  
 Brooks Kushman PC  
 601 South Figueroa Street  
 Suite 2080  
 Los Angeles, CA 90017-5726

*Attorneys for SNI LLC*